p14 expression differences in ovarian benign, borderline and malignant epithelial tumors

Abstract

BackgroundAbnormalities in tumor suppressors p14, p16 and p53 are reported in several human cancers. In ovarian epithelial carcinogenesis, p16 and p53 show higher immunohistochemical staining frequencies in malignant tumors and are associated with poor prognoses. p14 was only analyzed in carcinomas, with conflicting results. There are no reports on its expression in benign and borderline tumors. This study aims to determine p14, p16 and p53 expression frequencies in ovarian benign, borderline and malignant tumors and their associations with clinical parameters.MethodsA cross-sectional study utilizing immunohistochemistry was performed on paraffin-embedded ovarian epithelial tumor samples. Clinical data were collected from medical records. Fisher’s exact test and the Bonferroni correction were performed for frequency associations. Survival comparisons utilized Kaplan-Meier and log rank testing. Associations were considered significant when p < 0.05.Resultsp14 absent expression was associated with malignant tumors (60 % positive) (p = 0.000), while 93 % and 94 % of benign and borderline tumors, respectively, were positive. p16 was positive in 94.6 % of carcinomas, 75 % of borderline and 45.7 % of benign tumors (p = 0.000). p53 negative staining was associated with benign tumors (2.9 % positive) (p = 0.016) but no difference was observed between borderline (16.7 %) and malignant tumors (29.7 %) (p = 0.560). No associations were found between expression rates, disease-free survival times or clinical variables. Carcinoma subtypes showed no difference in expression.ConclusionsThis is the first description of p14 expression in benign and borderline tumors. It remains stable in benign and borderline tumors, while carcinomas show a significant absence of staining. This may indicate that p14 abnormalities occur later in carcinogenesis. p16 and p53 frequencies increase from benign to borderline and malignant tumors, similarly to previous reports, possibly reflecting the accumulation of inactive mutant protein. The small sample size may have prevented statistically significant survival analyses and clinical correlations. Future studies should investigate genetic abnormalities in p14 coding sequences and include all types of ovarian epithelial tumors. Bigger sample sizes may be needed for significant associations.

Usefulness of COL11A1 as a Prognostic Marker of Tumor Infiltration

“…There have been various biomarkers proposed to determine the malignant potential of borderline tumors, such as differential loss of p14 [ 66 ] in invasive tumors with respect to borderline, overexpression of interleukin 8 (IL-8) and its receptors [ 67 ], or multigenic signature to predict worse prognosis [ 68 ]; however, none of them have demonstrated high sensitivity rates.…”

miR‐200c overexpression inhibits the invasion and tumorigenicity of epithelial ovarian cancer cells by suppressing lncRNA HOTAIR in mice

“…Snail protein expression in xenograft tumor was detected by immunohistochemistry and Western blot. According to the method, 6 immunohistochemical staining results were determined. Sinicrope modified method was determined to obtain the quantitative positive results.…”

Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity

“…Until recent years, investigators have identified another important regulator in this p53/MDM2 pathway, the cyclin-dependent kinase inhibitor p14 ARF (termed p19 ARF in the mouse) [17]. The p14 ARF protein is an alternative reading frame protein product of the CDKN2A/INK4A locus [18]. The other one is p16 INK4A protein [17].…”